Melanoma, Experimental

• 

  Subject Areas on Research

  • A murine monoclonal antibody directed against the carboxyl-terminal domain of GRP78 suppresses melanoma growth in mice. 
  • A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. 
  • An NAD(P)H oxidase regulates growth and transcription in melanoma cells. 
  • Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. 
  • Antigen delivery by alpha(2)-macroglobulin enhances the cytotoxic T lymphocyte response. 
  • Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. 
  • Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. 
  • B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. 
  • Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. 
  • CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin. 
  • Chemotactic factor and P15E-related chemotaxis inhibitor in human melanoma cell lines with different macrophage content and tumorigenicity in nude mice. 
  • Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor. 
  • Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. 
  • Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. 
  • Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. 
  • Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors. 
  • Defective antitumor responses in CX3CR1-deficient mice. 
  • Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. 
  • Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. 
  • Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. 
  • Direct correlation between DNA repair capacity and metastatic potential of K-1735 murine melanoma cells. 
  • Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells. 
  • Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. 
  • Effects of hyperthermia and irradiation on the growth of mouse melanoma tumors following immunotherapy. 
  • Electric field-mediated transport of plasmid DNA in tumor interstitium in vivo. 
  • Electric fields in tumors exposed to external voltage sources: implication for electric field-mediated drug and gene delivery. 
  • Electromobility of plasmid DNA in tumor tissues during electric field-mediated gene delivery. 
  • Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. 
  • Enhanced binding and inertness to dehalogenation of alpha-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. 
  • Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. 
  • Enhancement of electric field-mediated gene delivery through pretreatment of tumors with a hyperosmotic mannitol solution. 
  • Enhancement of radiotherapy by hyperthermia-regulated gene therapy. 
  • Enhancing Radiation Therapy Through Cherenkov Light-Activated Phototherapy. 
  • Environmental and Genetic Activation of Hypothalamic BDNF Modulates T-cell Immunity to Exert an Anticancer Phenotype. 
  • Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. 
  • Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon. 
  • Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. 
  • Feasibility of estimating the temperature distribution in a tumor heated by a waveguide applicator. 
  • Fluorine-18-labeled [Nle4,D-Phe7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue. 
  • GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome. 
  • Gadolinium-conjugated gold nanoshells for multimodal diagnostic imaging and photothermal cancer therapy. 
  • Gene Expression Profile of Dendritic Cell-Tumor Cell Hybrids Determined by Microarrays and Its Implications for Cancer Immunotherapy. 
  • Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. 
  • Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. 
  • Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. 
  • Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells. 
  • Immune evasion by murine melanoma mediated through CC chemokine receptor-10. 
  • Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice. 
  • Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow. 
  • Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. 
  • In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. 
  • In vivo photoacoustic microscopy with 7.6-µm axial resolution using a commercial 125-MHz ultrasonic transducer. 
  • In-transit melanoma: the role of alkylating-agent resistance in regional therapy. 
  • Inhibition of the growth of human melanoma metastases in nude mice by melanoma-specific murine monoclonal antibody. 
  • Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. 
  • Interferon gamma (IFNgamma) gene transfer of an EMT6 tumor that is poorly responsive to IFNgamma stimulation: increase in tumor immunogenicity is accompanied by induction of a mouse class II transactivator and class II MHC. 
  • Isolated limb infusion as a model to test new agents to treat metastatic melanoma. 
  • Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. 
  • Label-free oxygen-metabolic photoacoustic microscopy in vivo. 
  • Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination. 
  • Mechanism of the Antitumor and Radiosensitizing Effects of a Manganese Porphyrin, MnHex-2-PyP. 
  • Modulation of murine B16F10 melanoma plasminogen activator production by a synthetic peptide derived from the laminin A chain. 
  • Modulation of specific active immunization against murine melanoma using recombinant cytokines. 
  • Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. 
  • Near-infrared optical imaging of B16 melanoma cells via low-density lipoprotein-mediated uptake and delivery of high emission dipole strength tris[(porphinato)zinc(II)] fluorophores. 
  • Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts. 
  • Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. 
  • Osteopontin has a protective role in prostate tumor development in mice. 
  • Peptide-conjugated PAMAM dendrimer as a universal DNA vaccine platform to target antigen-presenting cells. 
  • Pericyte-like location of GFP-tagged melanoma cells: ex vivo and in vivo studies of extravascular migratory metastasis. 
  • Pericytic-like angiotropism of glioma and melanoma cells. 
  • Photoablation of ocular melanoma with a high-powered argon endolaser. 
  • Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. 
  • Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. 
  • Preparation, cytotoxicity, and in vivo antitumor efficacy of 111In-labeled modular nanotransporters. 
  • Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. 
  • Regulation of local and metastatic host-mediated anti-tumour mechanisms by L-selectin and intercellular adhesion molecule-1. 
  • Responses of vascular endothelial cells to angiogenic signaling are important for tumor cell survival. 
  • Role of antioxidant enzymes in the induction of increased experimental metastasis by hydroxyurea. 
  • Serological response of non-human primates to human melanoma disialoganglioside GD3. 
  • Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. 
  • Superantigen enhanced protection against a weak tumor-specific melanoma antigen: implications for prophylactic vaccination against cancer. 
  • Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. 
  • The Abl interactor proteins localize to sites of actin polymerization at the tips of lamellipodia and filopodia. 
  • The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif. 
  • The effect of high intensity focused ultrasound treatment on metastases in a murine melanoma model. 
  • The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth. 
  • Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells. 
  • Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. 
  • Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines. 
  • Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity. 
  • Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. 
  • Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. 
  • Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. 
  • Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. 
  • VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. 
  • Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. 
  • Whole blood cells loaded with messenger RNA as an anti-tumor vaccine. 
  • Zinc alpha-2-glycoprotein regulates melanin production by normal and malignant melanocytes. 
• 

  Keywords of People

  • Cianciolo, George James, Associate Professor in Pathology, Pathology
  • Hanks, Brent A., Assistant Professor of Medicine, Pharmacology & Cancer Biology
  • Lee, Walter T, Associate Professor of Surgery, Radiation Oncology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Sanchez-Perez, Luis Ariel, Assistant Professor of Neurosurgery, Neurosurgery
  • Zhong, Xiaoping, Professor of Pediatrics, Immunology